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SulTlmary 
We studied the effects of histamine on human immunoglobulin (IgE) and IgG4 production. 
Histamine selectively enhanced IgE and IgG4 production in purified surface  IgE and IgG4 
negative  (slgE-slgG4-)  B  ceils from normal donors stimulated with interleukin  (IL)-4 plus 
anti-CD58 or IL-13 plus anti-CD58 monoclonal antibody (mAb) without affecting production 
of IgG1, IgG2, IgG3, IgM, IgA1, or IgA2. In cultures with IL-4 plus anti-CD58 mAb, hista- 
mine-induced enhancement of IgE and IgG4 production was specifically blocked by thiopera- 
mide (H3 receptor antagonist), and was inhibited by anti-IL-10 antibody (Ab). In contrast, in 
cultures with IL-13 plus anti-CD58 mAb, histamine-induced enhancement was blocked by di- 
maprit (H1 receptor antagonist), and was inhibited by anti-IL-6 mAb. Histamine also enhanced 
IgE and IgG4 production by in vivo-generated slgE  + and slgG4 + B  cells, respectively, from 
atopic patients; enhancement was blocked by dimaprit and thioperamide, and was inhibited by 
anti-IL-6 mAb and anti-IL-10 Ab. In slgE-slgG4- B ceils, IL-4 plus anti-CD58 mAb induced 
IL-10 production and IL-10 receptor expression, whereas IL-13 plus anti-CD58 mAb induced 
IL-6 production and IL-6 receptor expression. Histamine increased IL-10 and IL-6 production 
without affecting IL-10 and IL-6 receptor expression, in cultures with IL-4 plus anti-CD58 
mAb and with IL-13 plus anti-CD58 mAb, respectively,  which was blocked by thioperamide 
and dimaprit, respectively. In contrast, slgE + and slgG4 + B cells spontaneously produced both 
IL-6 and IL-10 and constitutively expressed  IL-6 and IL-10 receptors, and histamine increased 
IL-6 and IL-10 production without affecting IL-6 or IL-10 receptor expression, which was 
blocked by thioperamide and dimaprit. These results indicate that histamine enhanced IgE and 
IgG4 production by increasing endogenous IL-6 and IL-10 production via H, and H 3 recep- 
tors, respectively. 
M 
any cytokines and factors are involved in human IgE 
.and  IgG4  production.  IL-4 induces  IgE  and  IgG4 
production in purified B  cells stimulated with anti-CD40 
mAb, or hydrocortisone by isotype switching (1-5).  IL-6, 
IL-10,  and TNF-o~  enhance IL-4-induced IgE and IgG4 
production in such cultures, whereas IL-8, and TGF-[3 in- 
hibited IgE and IgG4 production (3, 6-9). In contrast,  IL-5, 
IL-9, IL-12, IFN-ot, and IFN-% which either enhance or 
inhibit  IgE  and  IgG4  production  induced by  IL-4  in  T 
cell-dependent culture,  have no  effect on  IgE  and IgG4 
production in purified B cells (9-12). These results indicate 
that there are various IgE- and IgG4-modulatory factors in 
IL-4--stimulated cultures. Recently, in addition to IL-4, IL-13 
has been shown to induce IgE and IgG4 production in pu- 
rified B cells stimulated with anti-CD40 mAb (13, 14). We 
have reported that IL-13 induces IgE and IgG4 production 
in purified B  cells stimulated with hydrocortisone (9,  15). 
Moreover, anti-CD58 mAb was also found to induce IgE 
production in IL-4--stimulated cultures (16). However, the 
effects  of various cytokines on  IgE and IgG4 production 
induced by  IL-4 plus  anti-CD58  mAb  or by IL-13 plus 
anti-CD58 mAb have not been studied in depth. 
Histamine is an autocoid released from mast cells and ba- 
sophils  by IgE- and IgG4-dependent stimulation (17, 18). 
It has been reported that histamine modulates production 
of cytokines by various cells, and that it enhances produc- 
tion of IL-6 and IL-8 by B  and endothelial cells, respec- 
tively, whereas  it inhibits  TNF-o~  production by mono- 
cytes (19-21).  In addition, histamine inhibits human IgG 
and IgM production in purified B ceils stimulated with Sta- 
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clear cells stimulated with pokeweed mitogen  (22,  23).  In 
contrast,  histamines  were  found  to  either  inhibit  or  en- 
hance  IgG  or IgM production in  human  B  cell lines  (22, 
24).  These  findings  indicate  that  histamine  differentially 
modulates Ig production depending on stimuli of target B 
cells.  Since the  effect of histamine  on  IgE  and  IgG4 pro- 
duction has not yet been reported, we examined the effect 
of histamine  on  their production in human  B  cells stimu- 
lated with  IL-4 plus anti-CD58  mAb,  or with  IL-13 plus 
anti-CD58 mAb. Modulation of the effect of histamine by 
various cytokines is also discussed. 
Materials  and Methods 
Reagents.  Histamine dihydrochloride (HIS) l, diphenhydranfine 
(DIP, H t receptor antagonist), dimaprit (DIM, H2 receptor ago- 
nist), cimetidine (CIM, H 2 receptor antagonist),  (tL)-0~-methyl- 
histamine (RAM, H3 receptor agonist), and thioperamide (THI, 
H3  receptor antagonist)  were  purchased from  Sigma Chemical 
Co. (St. Louis, MO). 2-methylhistamine (MET, H 1 receptor ago- 
nist) was kindly provided by Smith Kline & French (Philadelphia, 
PA). The following recombinant human cytokines and Abs were 
kindly provided by companies noted previously (1, 9,  14):  IL-4 
and rabbit anti-IL-4 Ab (Ono Pharmaceutical Company, Osaka, 
Japan),  IL-2  and  IFN-~x  (Takeda  Chemical  Industries,  Osaka), 
and growth hormone and rabbit anti-growth hormone Ab (Sum- 
itomo  Pharmaceutical  Company,  Osaka, Japan).  Recombinant 
human IL-13 was purchased from Pepro Tech Inc. (Rocky Hill, 
NJ). Recombinant human IL-6, IL-9, IL-10, IL-12, IFN-y, and 
TGF-]3, and mouse IgG1 anti-IL-6 and goat anti-IL-10 Ab were 
purchased from IL&D Systems, Inc. (Minneapolis, MN).  Mouse 
IgM anti-CD40  mAb  (BL-C4), mouse  IgG2a anti-CD58  mAb 
(BRIC5), and rabbit anti-IL-13 Ab were purchased from Cosmo 
Bio Co. (Tokyo, Japan). The culture medium was DME, supple- 
mented with Ham's Nutrient (DME/F-12; Sigma Chemical Co.), 
0.5% BSA, and 50 Ixg/ml transferrin (9, 14). 
Cell Cultures.  Tonsillar mononuclear cells were obtained from 
nonatopic donors  (serum  IgE level <50  U/ml)  and  atopic pa- 
tients (serum IgE level 1,578-12,259  IU/ml). Then, highly puri- 
fied  B  ceils  were  separated  by  S1LBC rosetting,  followed  by 
k-leucine methyl ester incubation, as described previously (9, 14). 
Purified B  cell fractions  contained  <1%  CD3 +  T  cells,  <1% 
C1)14 + monocytes, <1% CD16 + NK cells, and >98% CD20 + B 
cells. Purified B  cells were further separated into small resting B 
cells by Percoll density centrifugation, and small B cells were de- 
pleted of surface  IgE-positive (slgE +) and slgG4  + B cells by pan- 
ning  (9,  14).  The  percentage of sIgE + and slgG4  + B  cells was 
<0.1%.  These slgE-slgG4- B  cells were cultured (2  ￿  105/0.2 
ml/well) in U-bottomed microtiter plates (Costar Corp.,  Cam- 
bridge, MA) for 14 d in the presence or absence of various factors 
as described in tt,  esults.  Alternatively, slgE  +, slgE-, slgG4  +, and 
slgG4  B  cells were purified from tonsillar B  cells of atopic pa- 
tients  by panning.  The  percentages,  respectively, of slgE  +  and 
slgG4-  B  cells  in  the  slgE-  and  slgG4  B  cell fractions were 
<0.1%.  On  the  other hand,  purified slgE  + and  slgG4  + B  cell 
1Abbreviations used in  this paper: CIM,  cimetidine; DIM,  dimaprit; DIP, 
diphenhydramine; HIS, histamine; MET, 2-methylhistamine; MFI, mean 
fluorescence intensiw; RAM, (R)-oL-methylhistamine;  sIgE  +, surface IgE 
positive; THI, thioperamide. 
fractions  contained  >98%  slgE  +  B  cells  and  >98%  slgG4  +  B 
cells,  respectively (9,  14).  Purified  slgE  +,  slgE  ,  slgG4  +,  and 
slgG4- B  cells were cultured (2  ￿  104/0.2  ml/well) for 14 d as 
described in Results. Control cultures for the evaluation of pre- 
formed Ig were carried out in the presence of cycloheximide (100 
Ixg/ml). The amounts oflgE, IgG, IgM, and IgA subclasses in the 
supernatants were determined by ELISA (9, 15). In some experi- 
ments, slgE-slgG4-, slgE +, and slgG4  + B  cells were cultured 
(2 ￿  10s/0.2 ml/well) with various factors for 2 d, and the produc- 
tion oflL-6 and IL-10 was determined by ELISA (tL&D Systems, 
Inc.). Simultaneously, the binding of IL-6, IL- 10, (l<)-ot-methyl- 
histamine, and diphenhydramme to those cells was studied by us- 
ing biotinylated IL-6 and IL-10 (P,&D Systems, Inc.), and bioti- 
nylated (R)-ec-methylhistamine and diphenhydramine as previously 
reported (9). The mean fluorescence intensity (MFI) value ofbi- 
otinylated factor~specific binding, determined after the  subtrac- 
tion ofnonspecific binding in the presence of a 100-fold excess of 
unlabeled factors,  was expressed as AMFI (9). 
In  Vivo  Effect of Antihistamine  on  IgE  and  lgG4  Production  in 
Atopic Patients.  Four atopic patients (patients with atopic derma- 
tiffs, serum IgE level 2,344-5127 IU/ml, age 15-45-yr old) were 
treated with oral antihistanfine (clemastine, 6 mg/d) and nonste- 
roidal anti-inflammatory ointment (bufexamac ointment). Alter- 
natively, three atopic patients (patients with atopic dermatitis, se- 
rum IgE level 1,168-3685 IU/ml, age 16-32-yr old) were treated 
with bufexamac ointment alone. Peripheral blood was drawn be- 
fore and after 2 wk of each treatment, and large B cells were pnri- 
fled as above. They were  cultured  (2  ￿  10s/0.2  ml/well) with 
medium alone for 14 d, and the amount of IgE and IgG4 in the 
supernatants were determined by ELISA (9,  15). 
Results  and Discussion 
Initial experiments have shown that histamine, either alone 
or with  IL-4,  IL-13,  or anti-CD58  mAb,  did not  induce 
production  of IgE  (<0.2  ng/ml,  n  =  10)  or  IgG4  (<0.3 
ng/ml,  n  =  10)  by  slgE-slgG4-  B  cells.  However,  as 
shown in Fig. 1 A, histamine enhanced IgE and IgG4 pro- 
duction induced by IL-4 plus anti-CD58  mAb in a  dose- 
dependent fashion. In contrast, histamine did not affect pro- 
duction oflgM, IgG1, or IgG2 (Fig. 1 B) or IgA1, IgG3, or 
IgA2 (Fig. 1  C).  Identical results were observed in cultures 
stimulated with IL-13 plus anti-CD58 mAb. Histamine se- 
lectively enhanced production of IgE and IgG4 in a dose- 
dependent fashion (Fig. 1 D), without affecting production 
oflgM, IgG1, IgG2, IgG3, IgA1, or IgA2 (Fig. 1, E and F). 
In  10  experiments, histamine  (10 -5 M)  enhanced produc- 
tion of IgE  (264  +  87%  enhancement)  and  IgG4  (245  + 
92% enhancement)  induced by IL-4 plus anti-CD58 mAb, 
while it enhanced production of IgE (378  +  95% enhance- 
ment)  and  IgG4  (321  +  102%  enhancement)  induced by 
IL-13 plus anti-CD58 mAb. In contrast, histamine did not 
enhance  (<20%  enhancement)  production  of IgM,  IgG1, 
IgG2, IgG3, IgA1, or IgA2 in these cultures (n =  10). 
It has been reported that histamine modulates Ig produc- 
tion or cytokine synthesis through one of the H1, H> or H 3 
receptors, or through more than one type of receptor (19- 
24).  To  study which  receptors were involved in  enhance- 
ment of IgE and IgG4 production, B  cells were stimulated 
with  histamine,  and  HI,  H2,  and  H 3 receptor  antagonist 
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Figure 1.  Effects  of histamine on Ig production. Purified slgE-slgG4- 
B cells from nonatopic donors were cultured (10S/well) with IL-4 (1,000 
U/ml) plus anti-CD58 mAb (1 }xg/ml) (A-C), or IL-13 (500 ng/ml) plus 
anti-CD58 mAb (D-F) in the presence or absence of increasing concen- 
trations of histamine. After 14 d of culture, production of IgE, IgG4 (A 
and D), IgM, IgG1, IgG2 (B and E), IgA1, lgG3, and IgA2 (C and F) was 
determined. Values are means •  1 SD of triplicate cultures from one ex- 
periment, representative often. 
were  added. As shown  in Fig. 2  A,  left, in cultures stimu- 
lated  with  IL-4 plus  anti-CD58  mAb,  histamine-induced 
IgE  and  IgG4 production  was  not  affected by diphenhy- 
dramine (DIP, H1 receptor antagonist) or cimetidine (CIM, 
H 2 receptor antagonist),  whereas  enhancement  was  com- 
pletely blocked by thioperamide (THI,  H 3 receptor antag- 
onist). 
We have previously reported that, in purified B cells, IL-4 
plus hydrocortisone or IL-13 plus hydrocortisone induced 
IgE  and  IgG4  production,  and  this  production  was  en- 
hanced  by  IL-6  and  IL-10.  In  contrast,  other  cytokines, 
IL-1]3, IL-2, IL-3, IL-5, IL-7, IL-9, IL-11, or IL-12 did not 
enhance  IgE  or  IgG4  production  (9).  In  addition,  nerve 
growth  factor  or  growth  hormone,  which  enhanced  IgE 
and/or IgG4 production (1,  13), were without effect (data 
not shown).  It is thus possible that histamine-induced en- 
hancement was due to production of IL-4, IL-6, IL-10, or 
IL-13.  As  shown  in  Fig.  2  A,  left,  in  cultures  stimulated 
with IL-4 plus anti-CD58  mAb, IgE and IgG4 production 
was  completely abrogated by anti-IL-4 mAb.  In addition, 
histamine-induced enhancement was inhibited by anti-IL-10 
Ab, whereas neither anti-IL-6 mAb nor anti-IL-13 Ab did 
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Figure 2.  Effects of various factors on histamine-induced enhancement 
of IgE and IgG4 production.  Purified slgE-slgG4- B cells from non- 
atopic donors were cultured (105/well) with IL-4 (1,000 U/ml) plus anti- 
CD58 mAb (1 I.tg/ml) or IL-13 (500 ng/ml) plus anti-CD58 mAb in the 
presence or absence of the indicated factors. Histamine (HIS) was used at 
10 -5 M,  diphenhydramine (DIP), cimetidine (CIM), and thioperamide 
(THI) each at 10  4 M, all the Abs at 10 p.g/ml, and IL-6 and IL-10 each 
at 300 ng/ml. After 14 d of culture, lgE and lgG4 production were deter- 
mined. Values are means +  1 SD of triplicate cultures. 
so. In contrast, in cultures stimulated with IL-13 plus anti- 
CD58  mAb,  histamine-induced  enhancement  of IgE  and 
IgG4  production  was  blocked  by  diphenhydramine,  but 
not  by  cimetidine  or  thioperamide.  Moreover,  anti-IL-6 
mAb, but  not  anti-IL-4 mAb or anti-IL-10 Ab, inhibited 
histamine-induced enhancement,  and anti-IL-13 Ab abro- 
gated IgE and IgG4 production (Fig. 2 A, right). 
We then studied the specificity of the effects of IL-6 and 
IL-10.  As  shown  in  Fig.  2  B,  left,  in  cultures  stimulated 
with IL-4 plus anti-CD58 mAb, addition of IL-10, but not 
IL-6,  enhanced  IgE  and  IgG4  production.  Histamine- 
induced enhancement was blocked by anti-IL-10 Ab, which 
was reversed by high  concentrations of IL-10, but not by 
IL-6.  In  contrast,  in  cultures  stimulated  with  IL-13  plus 
anti-CD58 mAb, IL-6 enhanced IgE and IgG4 production. 
Anti-IL-6 blocked histamine-induced enhancement, which 
was reversed by IL-6, but not by IL-10. Collectively, these 
results indicated that in cultures stimulated with  IL-4 plus 
359  Kimata et al. anti-CD58  mAb,  histamine enhanced  IgE and  IgG4 pro- 
duction through H 3 receptors and by involvement oflL-10, 
but not oflL-6. This is in accordance with the previous re- 
port by others (16)  that IL-6 did not affect IgE production 
induced by IL-4 plus anti-CD58 mAb. In contrast, in cul- 
tures  stimulated  with  IL-13  plus  anti-CD58  mAb,  hista- 
mine enhanced  IgE and IgG4 production through  H l re- 
ceptors and by involvement of IL-6. 
It is possible that histamine enhanced IgE and IgG4 pro- 
duction by affecting isotype switching ofslgE- and slgG4- B 
cells,  respectively,  or  alternatively,  by  directly  affecting 
slgE §  and  slgG4 §  B  cells,  respectively.  To  test  this,  we 
took advantage of the fact that in vivo-generated slgE + and 
slgG4  +,  but not slgE-  and slgG4- B  cells  obtained from 
atopic patients spontaneously produced  IgE and IgG4, re- 
spectively (1,  14,  15). As shown in Fig. 3 A, Expt.  1, hista- 
mine enhanced IgE production by slgE § B cells, which was 
blocked by diphenhydramine and thioperamide, whereas ci- 
metidine and IFN-~/failed to do so.  Other inhibitory cy- 
tokines, IL-12, IFN-ot, TGF-[3, and Abs to stimulatory cy- 
tokines, including antigrowth hormone,  antinerve growth 
factor, and anti-IL-9 Abs were also without effect (data not 
shown).  However, histamine failed to induce  IgE produc- 
tion  by slgE-  B  cells  (Fig.  3  A,  Expt.  1).  On  the  other 
hand, spontaneous IgE production by slgE + B cells was not 
inhibited  by anti-lL-4 mAb or anti-IL-13 Ab,  whereas it 
was inhibited by anti-IL-6 mAb and anti-IL-10 Ab. More- 
over, anti-IL-6 m_Ab and anti-IL-10 Ab each inhibited his- 
tamine-induced enhancement of lgE production (Fig.  3 A, 
Expt.  2).  Furthemlore,  simultaneous addition  of anti-IL-6 
mAb and anti-IL-10 Ab almost completely inhibited spon- 
taneous and histamine-induced lgE production by slgE + B 
ceils.  IL-6  or  IL-10  each  partially  reversed  inhibition  by 
anti-IL-6 mAb plus  anti-IL-10 Ab.  However,  addition  of 
both IL-6 and IL-10 completely reversed inhibition of lgE 
production.  In contrast, histamine with these factors failed 
to induce IgE production by slgE- B cells (Fig. 3 A, Expt. 3). 
Moreover, histamine with IL-4, IL-t3, or anti-CD58 mAb 
did not induce IgE production by slgE- B cells  (<0.2 ng/ 
ml) as observed by slgE- B cells from nonatopic donors. 
As shown in Fig.  3 B, Expts.  1-3, identical results were 
observed for  IgG4 production  by slgG4  +  and  slgG4-  B 
cells.  Spontaneous IgG4 production by slgG4 + B cells was 
enhanced by histamine, IL-6, and IL-10, whereas it was in- 
hibited  by anti-IL-6 mAb  or  anti-IL-10  Ab,  but  not  by 
anti-IL-4 mAb  or anti-IL-13 Ab.  Histamine-induced  en- 
hancement was blocked by diphenhydramine and thiopera- 
mide, but not by dimaprit, and was inhibited by anti-IL-6 
mAb and anti-IL-10 Ab. Addition of both IL-6 and IL-10 
reversed inhibition  by anti-IL-6 mAb plus anti-IL-10 Ab, 
whereas histamine with these factors failed to induce IgG4 
production by slgG4- B  cells  (Fig.  3, Expt.  3).  Histamine 
with IL-4, IL-13, or with anti-CD58 mAb also failed to in- 
duce  IgG4 production  by slgG4-  B  cells  (<0.3  ng/ml). 
Taken together,  these  results indicated  that histamine  en- 
hanced  IgE  and  IgG4  production  by  directly  affecting 
slgE + and slgG4  + B cells,  respectively, via both H1 and H 3 
receptors and by involvement of IL-6 and IL-10. 
It is possible that histamine-induced enhancement of IgE 
and IgG4 production was due to the increase in IL-6 and/ 
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Figure 3.  Effects of histamine on IgE 
and IgG4 production by slg  + and slg  B 
cells from atopic patients. Purified slgE  + 
or slgE- (A), and slgG4  + or slgG4  (/3) t3 
cells were cultured (2  ￿  109well) with 
indicated  factors. Histamine (HIS) was 
used at 10 -5 M, diphenhydramine (DIP), 
cimetidine  (CIM),  and  thioperamide 
(THI) each at 10  4 M, IFN-y at 1,000 U/ 
nil, IL-6 and  IL-10 each at 300  ng/ml, 
and all the Abs at 10 txg/ml. After 14 d of 
culture, the  production of IgE  (A)  and 
IgG4  (B)  was  determined. Values are 
means -+ 1 SD of triplicate cultures. 
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expression  of IL-6  and/or  IL-10  receptors,  in  slgE  +  and 
slgG4 +  B  cells,  respectively.  To  study  this  possibility  di- 
rectly, we stimulated  slgE-slgG4-  B  cells  from nonatopic 
donors with IL-4 plus anti-CD58 m_Ab, or with IL-13 plus 
anti-CD58  mAb.  Alternatively,  slgE*  and  slgG4 +  B  cells 
from  atopic  patients  were  cultured  with  medium.  These 
cells were incubated with histamine in the presence or ab- 
sence of histamine receptor antagonists or agonists, and pro- 
duction of IL-6 and IL-10, and IL-10 receptor expression 
were  determined.  In slgE-slgG4-  B  cells,  medium  alone 
did not induce production oflL-6 or IL-10 (<0.01 ng/n'fl), 
or  expression  of IL-6  or  IL-10  receptors.  However,  as 
shown in Fig. 4 A, IL-4 plus anti-CD58 mAb induced IL-10 
production and IL-10 receptor expression, whereas it failed 
to  induce  IL-6  production  or  IL-6  receptor  expression. 
Histamine  enhanced  IL-10  production  without  affecting 
IL-10 receptor expression,  whereas  histamine  failed to in- 
duce IL-6 production or IL-6 receptor expression. Histamine- 
induced  enhancement  of IL-10 production  was  blocked 
by thioperamide,  but not by dimaprit.  Moreover, whereas 
2-methylhistamine (MET, H 1 receptor agonist) or dimaprit 
(DIM,  H2  receptor  agonist)  failed to  enhance  IL-10 pro- 
duction,  (R)-oe-methylhistamine  (RAM,  H 3 receptor ago- 
nist)  did  enhance  production.  On  the  other  hand,  IL-13 
plus  anti-CD58  mAb  induced  IL-6 production  and  IL-6 
receptor expression,  while  having no effect on IL-10 pro- 
duction or IL-10 receptor expression.  Histamine enhanced 
IL-6  production  without  affecting  IL-6  receptor  expres- 
sion,  and enhancement was blocked by diphenhydramine, 
but  not by thioperamide.  In addition,  (P,)-oL-methylhista- 
mine  enhanced  IL-6  production,  whereas  2-methylhista- 
mine or dimaprit failed to do so  (Fig.  4  B).  In contrast,  as 
shown in Fig. 4,  C  and D, slgE + and slgG4 + B  cells  from 
atopic patients spontaneously produced both IL-6 and IL-10, 
and  expressed  IL-6  and  IL-10  receptor.  Histamine  en- 
hanced  production  of IL-6 and  IL-10 without  affecting 
receptor  expression,  which  was  specifically  blocked  by 
diphenhydramine  and  thioperamide,  respectively.  More- 
over,  2-methylhistamine  and  (P,.)-ot-methylhistamine,  re- 
spectively, enhanced production of IL-6 and IL-10 without 
affecting  IL-6  and  IL-10  receptor  expression.  Taken  to- 
gether, enhancement of IgE and IgG4 production by hista- 
mine was due to the increase in production of IL-6 and/or 
IL-10, but not due to the increased expression of IL-6 and 
IL-10 receptors. 
In these studies, we have demonstrated that histarmne se- 
lectively  enhanced  IgE  and  IgG4  production.  However, 
the  mechanisms  of the  histamine-induced  enhancement 
differed depending on the culture systems used. In cultures 
of slgE-slgG4  B  cells  stimulated  with  IL-4  plus  anti- 
CD58  mAb,  histamine-induced  enhancement  was  due  to 
the  increased  production  of IL-10  through  H 3 receptors. 
This is not surprising.  It has been reported that, in addition 
to functional presynaptic autoreceptors in the brain cortex, 
H 3 receptors were involved in IL-8 secretion by endothe- 
lial cells,  contractions  of the  ileum,  and corticosterone  se- 
cretion by the  adrenal  cortex  (20,  25,  26).  To  the best of 
our  knowledge,  this  is  the  first  report  that  H 3 receptors 
were involved in  IL-10 production,  resulting in enhance- 
ment oflgE and lgG4 production. In accordance with this, 
as  shown  in  Fig.  5,  although  H 3 receptors  were  not  ex- 
pressed  on  freshly  separated  sIgE-slgG4-  B  cells  (<3 
AMFI), they were induced by IL-4 plus anti-CD58  mAb, 
but  not  by  IL-13  plus  anti-CD58  mAb  (<3  AMFI).  In 
contrast,  H 3 receptors  were  constitutively expressed  on in 
vivo-generated slgE + and slgG4 + B  cells. 
On  the  other  hand,  in  cultures  stimulated  with  IL-13 
plus  anti-CD58  mAb,  histamine  enhanced  IgE  and  IgG4 
production  through  increased  production  of IL-6 via  H 1 
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Figure 4.  Effects of histamine or histamine 
receptor agonists on the production and the bind- 
ing of IL-6 and IL-10. Purified slgE-slgG4- B 
cells from nonatopic donors were cultured with 
IL-4 plus anti-CD58 mAb (A), or with IL-13 
plus anti-CD58  mAb (B), whereas slgE  + (C) 
and  slgG4  +  (D)  B cells from atopic patients 
were cultured with medium or indicated fac- 
tors. Histamine was used at 10 -s M, other fac- 
tors at 10  -4 M. After 2 d of  culture, the produc- 
tion and the binding of IL-6 and IL-10 were 
determined. Values are means +  1 SD of tripli- 
cate cultures. 
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Figure  5.  Histamine receptor expression on  various cells. Purified 
slgE slgG4  B cells from nonatopic donors were cultured with medium 
(A), IL-4 plus anti-Cl)58 mAb (A), or with IL-13 plus anti-CD58 mAb 
(B), whereas slgE  + (C) and slgG4  + (D) B cells from atopic patients were 
cultured with medium. After 2 d of culture, the binding of (R)-~x-meth- 
ylhistamine (H~ receptor) and diphenhydramine (H~ receptor) was deter- 
mined. Values are the means -+ 1 SI) of  four experiments. 
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Figure 6.  Effect  of oral antihistamine on lgE and lgG4 production in 
atopic patients. Patients with atopic dermatitis were treated with oral anti- 
histamine (c/emastine) and nonsteroidal anti-inflammatory ointment (bu~,x- 
amac) (patients 1-4)  (A) or with bufexamac ointment alone (patients 5-7) 
(B). Peripheral blood B cells from patients before and after each treatment 
were cultured wtih nledium alone. After 14 d of culture, lgE and IgG4 
production was determined. Values are the means -+  1 SD of triplicate 
cultures. 
receptors. This is in accordance with the report that (a) IL-13 
increased IL-6 production by human keratinocytes, and (b) 
histamine  enhanced  IgM  production  through  increased 
production  of IL-6  via  H I  receptors  in  B  cells  (24,  27). 
Moreover,  as shown in Fig.  5,  H1  receptors  were not ex- 
pressed on slgE-slgG4- B cells  (<3 AMFI), however, they 
were  induced by IL-13 plus  anti-CD58  mAb,  but  not by 
IL-4 plus anti-CD58 mAb (<3  AMFI). In contrast, H I re- 
ceptors were expressed constitutively on in vivo-generated 
slgE + and slgG4 + B cells. 
Taken together,  these  results  suggested that in vivo IgE 
and IgG4 production was regulated by both IL-6 and IL-10, 
whereas in vitro IgE and IgG4 production induced by IL-13 
or IL-4 plus anti-CD58 mAb was regulated by IL-6 or IL-10 
independently.  Although we and others have reported that 
IL-6 and IL-10 enhance in vitro IgE and IgG4 production 
in various culture systems (3, 5, 6, 9), the direct evidence of 
the  effect oflL-6 and IL-10 on in vivo IgE and  IgG pro- 
duction in humans has not been previously reported. How- 
ever,  IL-6 is released  locally in antigen-challenged  sites  in 
atopic  patients  (28).  IL-10 is  overexpressed  in  the  skin  of 
patients  with  atopic  dermatitis  (29).  It  is  possible  that  in 
atopic patients, production oflL-6 and IL-10 is increased at 
the  local site,  which may enhance  IgE and  IgG4 produc- 
tion  there,  thus  resulting  in  aggravating  IgE-  and  IgG4- 
mediated allergic reactions (18). This possibility is currently 
under investigation. 
The fact that histamine enhanced IgE and IgG4 produc- 
tion stimulated with IL-4 or IL-13 is important in relation 
to  the  treatment  of allergic  diseases.  It has  been  reported 
that IL-4 increased histamine release from basophils (30). In 
addition,  we  have  found that  IL-13  (500  ng/ml)  also  in- 
creases histamine  release from human basophils  (21  +  6%, 
n  =  4).  Conversely,  IgE and  IgG4 were  also  involved in 
histamine release and IL-4 production (18, 31).  Therefore, 
it  is  tempting  to  speculate  that,  in  atopic  patients,  IL-4, 
IL-13 and histamine  may produce a  vicious circle.  Treat- 
ment with antihistamines  may decrease IgE and IgG4 pro- 
duction,  resulting  in  improvement  of allergy.  Therefore, 
we studied the effect of oralantihistamine  on IgE and IgG4 
production in atopic patients.  As shown in  Fig.  6,  sponta- 
neous  IgE  production  by  B  cells  from  atopic  patients 
treated  with  oral  H 1 receptor  antagonist,  clemastine  (and 
nonsteroidal  anti-inflammatory  ointment,  bufexamac)  for 
14 d, was decreased after treatment.  Similarly, spontaneous 
IgG4 production by B  cells from atopic patients  decreased 
after treatment with clemastine  (Fig.  6 A).  In contrast,  IgE 
and IgG4 production by B cells from atopic patients treated 
362  Histamine Enhances Human IgE and IgG4 Production with  bufexamac  ointment  alone,  as controls,  was  not  de- 
creased  after  treatment.  These  results  indicate  that  hista- 
mine may affect IgE and IgG4 production in vivo. Studies 
on the detailed mechanisms as well as molecular analysis for 
the  effect  of histamine  are  currently  in  progress.  Finally, 
histamine seems to be an excellent reagent for the study of 
IgE and IgG4 production. 
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